March 10, 2021 07:00 AM ESTUpdated March 12, 01:32 PM
R&D
Coronavirus

Eli Lil­ly tops up pos­i­tive PhI­II da­ta for its Covid-19 an­ti­body com­bo at ‘the op­ti­mal dose’

John Carroll

Editor & Founder

Eli Lil­ly has added an­oth­er brick in the wall of pos­i­tive da­ta as­sem­bled for its com­bo an­ti­body ther­a­py for Covid-19.

Its BLAZE-1 Phase III study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times